Compare GRMN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRMN | NTRA |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4B | 47.4B |
| IPO Year | 2000 | 2015 |
| Metric | GRMN | NTRA |
|---|---|---|
| Price | $279.69 | $350.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $256.40 | ★ $259.07 |
| AVG Volume (30 Days) | 612.1K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 17.67 | 0.65 |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $7,245,519,000.00 | $210,939,000.00 |
| Revenue This Year | $12.15 | $18.08 |
| Revenue Next Year | $8.69 | $19.65 |
| P/E Ratio | $135.24 | ★ N/A |
| Revenue Growth | ★ 15.06 | N/A |
| 52 Week Low | $186.67 | $157.43 |
| 52 Week High | $314.28 | $343.18 |
| Indicator | GRMN | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 59.60 |
| Support Level | $228.04 | $316.00 |
| Resistance Level | $314.28 | $343.18 |
| Average True Range (ATR) | 5.62 | 9.17 |
| MACD | -1.58 | -2.24 |
| Stochastic Oscillator | 56.75 | 45.20 |
Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.